Uveal melanoma (UM) exhibits recurring chromosomal abnormalities and gene driver mutations, which are related to tumor evolution/progression. Almost half of the patients with UM develop distant metastases, predominantly to the liver, and so far there are no effective adjuvant therapies.
implications for implementation of patient surveillance, properly designed clinical trials enrollment, and adjuvant therapy.
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| I N TR ODU C TI ON
Uveal melanoma (UM) is a rare malignancy arising from uveal melanocytes. Current diagnosis of UM is based on both the clinical experience of the specialist and diagnostic techniques such as indirect ophthalmoscopy, ultrasonography scans, fundus fluorescein angiography, and transillumination. 1 Despite the wide range of therapeutic options, including local radiotherapy, surgical resection and phototherapy, almost half of the patients with UM develop distant metastases, predominantly to the liver. 2 The poor outcome of UM patients with metastatic disease derives from the absence of proven effective adjuvant therapies. 3, 4 UM prognosis is based on clinicopathologic factors, and, most importantly, on molecular and genetic markers. [5] [6] [7] [8] [9] [10] UM typically exhibits recurring chromosomal abnormalities, which are related to tumor progression. 11 Recently, Yavuzyigitoglu et al. 12 hypothesized that UM with specific mutations are characterized by different mechanisms causing different types of chromosomal abnormalities. Chromosome alterations correlated with reduced UM patient survival are chromosome 3 loss, chromosome arm 8q gains and loss of chromosome arm 1p (reviewed in 3). UM also shows a pattern of recurrent mutations. Mutations in GNAQ and GNA11 are early events that promote cell proliferation. Mutations in BAP1, SF3B1, and EIF1AX represent later events that are largely mutually exclusive. BAP1 mutations are associated with rapid metastatic progression and EIF1AX mutations with prolonged metastatic-free survival. [13] [14] [15] SF3B1 mutations have an intermediate risk and are associated with late metastasis. 16 Predictive information on the clinical outcome of UM patients could provide the basis to determine an individualized, targeted therapeutic strategy for each UM patient. To reach this goal, it is important to have an accurate prediction system to assess the individual patient's metastatic risk. In this study, we evaluated clinical, pathologic, and genetic features of a UM series, and analyzed their associations with metastatic progression.
| M A TE RI A L S A ND M E TH ODS

| Patients
Tissue samples were obtained from 63 primary UM after enucleation surgery at E.O. Galliera Hospital, Genoa, Italy, between December 2005 and June 2016. Written informed consent was obtained from all patients.
Follow-up data were available for 61 patients, as shown in Table 1 .
| Tissue sampling and histopathological analysis
Tumor sampling was performed immediately after enucleation by transscleral fine-needle aspiration biopsy (FNAB) or by transscleral incisional biopsy. After marking the tumor boundary using transpupillary transillumination, FNAB was performed with a 25-gauge needle attached to a 10-ml syringe using manual aspiration with a biopsy gun. 
| Microsatellite analysis (MSA)
Twelve polymorphic microsatellite repeats on chromosome 3 were chosen to perform MSA (Supporting Information Table 2 ). PCRs were for IHC procedure. Two independent observers (RB and MR) scored the slides with no prior knowledge of the UM chromosome 3 status.
| Statistical analysis
Fisher's exact test was used to detect associations between the prevalence of metastasis and main discrete dichotomous factors. Univariate survival analysis of time to metastasis was performed using the Kaplan-Meier method (log-rank test), considering the date of enucleation as starting point and the date of metastasis diagnosis as endpoint.
Data were censored on the date of last follow-up. Cox Proportional
Hazard modelling was employed to estimate hazard ratios (HRs), adjusting for age, tumor stage (T), and sex. Statistical analysis was performed using STATA statistical package (version 14, Stata Corp, College
Station, Texas, USA).
| RE S U L TS
| Clinical-pathological findings
The study cohort comprised 63 UM patients, consisting of 40 men (63%) and 23 women (37%), with a median age at the time of eye enucleation of 64 years (range 28-89 years) and a median follow-up time of 3 years (interquartile range, IQR: 2-6 years). Thirty-five out of 63 (56%) patients had developed uveal melanoma metastases to the liver (mean time to metastasis 25.7 months; range 0-97 months). All the data relating to the patients, the pathological T stages, the UM histological cell type, and follow-up are summarized in Table 1 .
| MLPA and MSA
The distribution of gains in chromosome arms 8q and 6p, chromosome among the 51 UM cases with one or both these two imbalances, 33 cases showed monosomy 3 and 8q gain, 10 had monosomy 3, and 8 had 8q gain.
| Mutation analysis
GNAQ mutations were detected in 20/63 (32%), and GNA11 mutations in 25/63 (40%) UM samples ( Figure 1 and Table 2 ). In GNAQ, all the
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BAP1 coding regions and splice sites sequencing was successful in 60/63 (95%) UM samples, due to poor DNA quality/quantity of three samples (UM9, UM14, and UM49). BAP1 mutations were identified in 31/60 (52%) UM samples: 28 cases with monosomy 3 and 3 with isodisomy 3 ( Figure 1 and Table 2 ). In 6 UM samples with monosomy 3 (UM16, UM28, UM31, UM36, UM43, and UM48), Sanger sequencing showed a BAP1 heterozygous mutation (Table 2 ). Thirteen out of 31 (42%) UM had in-frame mutations, consisting in 10 missense mutations and 3 in-frame deletions. To predict the possible impact of the amino acid substitutions due to the different missense mutation on the structure and function of BAP1 protein, Polyphen-2 20 (genetics.bwh.harvard.edu/ pph2/index.shtml) and SIFT 21 (sift.jcvi.org) were used ( Table 2) .
Out-of-frame mutations were present in 18/31 (58%) UM: 13 samples had frameshift insertions/deletions, two samples splice site mutations, two samples nonsense mutations, and 1 sample a readthrough mutation ( Table 2 Information Table 3 ). BAP1 promoter methylation analysis was conducted in 3/11 tumors with discrepancy between IHC and sequencing (loss of BAP1 protein expression and no BAP1 mutation), but no hypermethylation was detected (Supporting Information Figure   3 ). SF3B1 mutations were identified at R625 codon in 6/61 (10%) UM:
5/6 SF3B1 mutations occurred in UM with BAP1 wt and positive IHC, and 1/6 in a UM with BAP1 wt but with negative IHC (Figure 1 and Table 2 ). Five out of 60 (8%) UM had a missense mutation in the EIF1AX gene ( Figure 1 and Table 2 ), in either exon 1 (UM32, UM52
and UM60) or exon 2 (UM27 and UM51). Two out of 5 EIF1AX mutations were found in cases with monosomy 3, BAP1 mutation, and loss of BAP1 nuclear immunostaining.
| BAP1 IHC
BAP1 IHC was successful in 62/63 cases (for UM06 no FFPE tumor material was still available), (Figure 1 ). Nineteen out of 62 (31%) UM samples showed a BAP1 nuclear positive immunostaining, and 43/62 (69%) were IHC negative (Figure 2A, B) . In positive UM samples, BAP1
staining did not show any intratumoral heterogeneity. Among the 43 UM with negative nuclear IHC, 4 UM samples (UM14, UM23, UM40, and UM48) showed a cytoplasmic signal (Table 2 and Figure 2C ), and 7
(UM16, UM28, UM31, UM36, UM38, UM43, and UM48) showed immune-cell infiltration (Table 2 and Figure 2D ). 
| Statistical analysis-associations between mutations and distant progression free survival (DPFS)
Univariate associations between studied parameters and metastatic disease were performed using the Fisher's exact test (Table 3) . Significant associations with DPFS were found for monosomy 3 (P 5 0.008), gain of 8q (P 5 0.012), BAP1 mutation (P 5 0.019), and loss of BAP1 protein expression (P 5 0.005). Conversely, gain of 6p was associated with the absence of liver metastases (P 5 0.019).
As regards time-to-event analysis, after a median follow-up time of (Figure 3 ). The presence of monosomy 3 and 8q gain together was associated to metastatic disease (log rank P 5 0.004) (Supporting Information Figure 4 ). Since no events were registered in the group without UM specific chromosome imbalances (n 5 7 subjects), we could not estimate HRs by COX model.
| D I SCUSSION
Specific cytogenetic alterations are associated with metastatic progression in UM. 22 According to previous results, monosomy 3 and 8q gain were found to be associated with metastatic UM, and 6p gain with a good prognosis. [22] [23] [24] [25] [26] [27] [28] Monosomy 3 together with 8q gain was found associated with metastatic disease, as already reported. [23] [24] [25] [26] In our series, also monosomy 3 without 8q gain (n 5 9) was associated with metastases, in contrast with previous data derived from larger cohorts. [26] [27] [28] In addition to MLPA, MSA was used to identify cases with isodisomy 3, which carries the same prognostic significance as monosomy 3 but is not detected by MLPA, as well as by all the techniques that measure the number of chromosomes, ie, FISH and CGH. 29 In our series, isodisomy 3 was found in 6% of all UM cases (9% of UM with monosomy 3), a frequency comparable to that reported in the few reports wherein two different prognostic tests have been performed on the same tumor samples to identify isodisomy 3. [29] [30] [31] The relatively small sample size could explain the difference between GNAQ and GNA11 mutation frequency in our series (72%) and the one reported in the literature (over 80% 3, 32 ). Recently, very low GNAQ and GNA11 mutation rates have been described in UM from Greek patients (overall GNAQ/GNA11 mutation frequency 42%) and Chinese patients (overall mutation frequency 38%). 33, 34 Until now, the difference in the reported frequencies of GNAQ/GNA11 mutations among the various study populations did not allow conclusions on inter-ethnic differences. The relationship between BAP1 loss and metastatic progression is reinforced by multiple independent studies. 35, 36 BAP1 is a tumor suppressor gene, involved in maintaining genome integrity through multiple mechanisms. [37] [38] [39] Until recently, it was thought that nuclear localization was required for all BAP1 functions. Recent experiments, however, showed a novel BAP1 cytoplasmic activity: wt BAP1 localizes at the endoplasmic reticulum, and has a role in promoting apoptosis via Ca21 mitochondrial changes. 40 Moreover, it was shown that cells from individuals carrying heterozygous germline BAP1 mutations have a distinctive metabolic signature, consisting in impairment of mitochondrial respiration and increase of aerobic glycolysis leading to a Warburg effect. 41 Metastatic potential and prognosis in UM lacking BAP1 functions could be influenced also by these mechanisms, Warburg effect creating an environment that promotes tumor growth in hypoxia, and impaired apoptosis increasing the resistance to chemotherapy-induced apoptosis. BAP1 protein activity depends on the deubiquitinating domain and, for its nuclear activities, on nuclear localization signals.
Missense mutations, which are mainly found in the UCH domain, can impair the catalytic domain. [42] [43] [44] Frameshift mutations can give rise to abnormal mRNAs, subjected to nonsense-mediated RNA decay, 45 These data are in agreement with previous reports, showing that the effect of missense mutations on BAP1 expression and localization is the loss of BAP1 IHC nuclear staining, and at times cytoplasmic accumulation of inactive mutated BAP1. 16, 35, 40, 47, 48 Eighteen samples had truncating or read-through BAP1 mutations, and all showed the absence of BAP1 nuclear immunostaining. Previous studies showed that the consequence of out-of-frame mutations is the absence of BAP1 nuclear protein, with some exceptions. 16, 49 In our UM series, univariate analysis showed that chromosome 3 monosomy, 8q gain, BAP1 mutations, and loss of BAP1 nuclear immunostaining were all significantly associated with metastatic progression, in agreement with previous studies. 50 showed hemizygous deletion of one or more BAP1 exons in a proportion of UM with monosomy 3, negative BAP1
IHC and BAP1 wt by Sanger sequencing, and Yoshikawa et al. 57 demonstrated that the discrepancy between BAP1 IHC (negative) and BAP1 mutational status (wt) in malignant mesothelioma was due to BAP1 deletions, which were too large to be detected by Sanger sequencing.
Although many studies have included substantial numbers of UM cases, those that have provided detailed mutational and cytogenetic data are quite few. 58 In this regard, the present study contributes to defining the genetic UM landscape. 
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